As of today (2024-04-19), Cerus's share price is $1.645. Cerus's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.28. Hence, Cerus's Price to Tangible Book Ratio of today is 5.81.
The historical rank and industry rank for Cerus's Price-to-Tangible-Book or its related term are showing as below:
CERS'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.81 Med: 10.16 Max: 14.19
Current: 5.88
During the past 13 years, Cerus's highest Price to Tangible Book Ratio was 14.19. The lowest was 5.81. And the median was 10.16.
CERS's Price-to-Tangible-Book is ranked worse than 76.35% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 2.58
vs CERS: 5.88
A closely related ratio is called PB Ratio. As of today, Cerus's share price is $1.645. Cerus's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.29. Hence, Cerus's P/B Ratio of today is 5.67.
Cerus Price-to-Tangible-Book Historical Data
The historical data trend for Cerus's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Cerus Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Price-to-Tangible-Book
10.96
11.36
14.19
9.79
7.63
Cerus Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Price-to-Tangible-Book
9.79
9.34
8.98
6.25
7.63
Competitive Comparison
For the Medical Devices subindustry, Cerus's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cerus Price-to-Tangible-Book Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Cerus's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Cerus's Price-to-Tangible-Book falls into.
Cerus Price-to-Tangible-Book Calculation
Cerus's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Cerus Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Cerus's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CERS has been successfully added to your 